Characteristics | Replanning group | Non-replanning group | P-value |
Number of patients | 11 | 11 |
|
Age (range) | 76 (44 - 81) | 68 (53 - 83) | 0.41 |
Sex |
|
| 0.31 |
Male | 7 | 10 |
|
Female | 4 | 1 |
|
BMI (kg/m2) | 24.4 | 22.5 | 0.55 |
(range) | (17.0 - 28.66) | (15.9 - 28.7) |
|
Primary tumor site |
|
| 0.32 |
Nasopharynx | 1 | 3 |
|
Oropharynx | 3 | 1 |
|
Hypopharynx | 3 | 2 |
|
Larynx | 3 | 1 |
|
Maxillary sinus | 0 | 2 |
|
Ethmoid sinus | 0 | 1 |
|
Nasal cavity | 1 | 0 |
|
Oral tongue | 0 | 1 |
|
Pathological diagnosis |
|
| 0.33 |
Squamouscell carcinoma | 11 | 9 |
|
Undifferentiated carcinoma | 0 | 1 |
|
Neuroblastoma | 0 | 1 |
|
Nodal staging |
|
| 1.00 |
N0 | 3 | 3 |
|
N1 | 3 | 3 |
|
N2 | 5 | 5 |
|
RT |
|
| 0.53 |
Definitive RT | 9 | 10 |
|
Postoperative RT | 2 | 1 |
|
Prescription doses of RT | 70 (60 - 70) Gy | 70 (60 - 70) Gy | 0.17 |
70 Gy | 9 | 7 |
|
66 Gy | 0 | 3 |
|
60 Gy | 2 | 1 |
|
Chemotherapy |
|
| 0.11 |
Carboplatin | 1 | 3 |
|
Docetaxel | 3 | 1 |
|
Cisplatin | 1 | 3 |
|
Cetuximab | 4 | 0 |
|
None | 2 | 4 |
|
Timing of the rescan from the initiation of RT | |||
Fractions | 15 (14 - 19) | 15 (13 - 18) | 0.69 |
Days | 21 (17 - 30) | 20 (17 - 27) | 0.91 |
BMI at rescan (kg/m2) | 23.1 | 21.3 | 0.78 |
(range) | (16.5 - 27.9) | (14.4 - 27.3) |
|
Weight loss from the initiation of RT to the rescan (%) | |||
(range) | 5.4 (1.7 - 11.2) | 4.1 (−3.2 - 9.2) | 0.19 |